Eye On Growth: Gabrielle Sulzberger Adds $229K Of Eli Lilly Stock To Portfolio

On November 20, Gabrielle Sulzberger, Director at Eli Lilly LLY executed a significant insider buy, as disclosed in the latest SEC filing.

What Happened: In a significant move reported in a Form 4 filing with the U.S. Securities and Exchange Commission on Wednesday, Sulzberger purchased 315 shares of Eli Lilly, demonstrating confidence in the company's growth potential. The total value of the transaction stands at $229,916.

Eli Lilly shares are trading down 1.56% at $741.66 at the time of this writing on Thursday morning.

Discovering Eli Lilly: A Closer Look

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.

Eli Lilly: Delving into Financials

Revenue Growth: Eli Lilly's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 20.43%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.

Insights into Profitability:

• Gross Margin: The company sets a benchmark with a high gross margin of 81.02%, reflecting superior cost management and profitability compared to its peers.

• Earnings per Share (EPS): Eli Lilly's EPS is below the industry average. The company faced challenges with a current EPS of 1.08. This suggests a potential decline in earnings.

Debt Management: With a high debt-to-equity ratio of 2.19, Eli Lilly faces challenges in effectively managing its debt levels, indicating potential financial strain.

Valuation Overview:

• Price to Earnings (P/E) Ratio: Eli Lilly's stock is currently priced at a premium level, as reflected in the higher-than-average P/E ratio of 81.19.

• Price to Sales (P/S) Ratio: With a relatively high Price to Sales ratio of 16.67 as compared to the industry average, the stock might be considered overvalued based on sales performance.

• EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation & Amortization): With an EV/EBITDA ratio of 59.36, the company's market valuation exceeds industry averages.

Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.

Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.

Exploring the Significance of Insider Trading

Emphasizing the importance of a comprehensive approach, considering insider transactions is valuable, but it's crucial to evaluate them in conjunction with other investment factors.

From a legal standpoint, the term "insider" pertains to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities as outlined in Section 12 of the Securities Exchange Act of 1934. This encompasses executives in the c-suite and significant hedge funds. These insiders are mandated to inform the public of their transactions through a Form 4 filing, to be submitted within two business days of the transaction.

A company insider's new purchase is a indicator of their positive anticipation for a rise in the stock.

While insider sells may not necessarily reflect a bearish view and can be motivated by various factors.

Cracking Transaction Codes

When analyzing transactions, investors tend to focus on those in the open market, detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase,while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.

Check Out The Full List Of Eli Lilly's Insider Trades.

Insider Buying Alert: Profit from C-Suite Moves

Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. Click here for access.

This article was generated by Benzinga's automated content engine and reviewed by an editor.